Evidence map›Paper›PMID 42104036›Full record

Trial reportAnnals of surgical oncology2026

Efficacy and Safety of Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Recurrent Uterine Leiomyosarcoma: Results of a Phase 2 Study.

Beatrice J Sun, Maggie Y Zhou, Marti Lohman, Ryan Mokhtari, Amanda Siy, Kristen Cunanan, Kristen N Ganjoo, Byrne Lee

Abstract readClinical Trial, Phase II
PubMed Publisher
In one paragraph

Trial report in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Beatrice J Sun *Surgical Oncology, Department of Surgery, Stanford University School of Medicine, Stanford, CA, USA.
Maggie Y Zhou *Sarcoma Program, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Marti LohmanSarcoma Program, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Ryan MokhtariSarcoma Program, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Amanda SiySarcoma Program, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Kristen CunananQuantitative Sciences Unit, Department of Medicine, Stanford University, Palo Alto, CA, USA.
Kristen N GanjooSarcoma Program, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Byrne LeeSurgical Oncology, Department of Surgery, Stanford University School of Medicine, Stanford, CA, USA. byrnelee@stanford.edu.ORCID http://orcid.org/0000-0002-1950-0262

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundUterine leiomyosarcoma (uLMS) is an aggressive malignancy with high rates of peritoneal recurrence and poor survival. Although surgery for recurrent uLMS has shown encouraging results, addition of hyperthermic intraperitoneal chemotherapy (HIPEC) is not well described. We evaluate safety and efficacy of cytoreductive surgery (CRS)-HIPEC with gemcitabine followed by systemic dacarbazine for recurrent uLMS. PATIENTS AND

methodsThis was an open-label, single-arm phase 2 study of patients with recurrent uLMS who underwent CRS-HIPEC at a single tertiary center (March 2021-May 2025). HIPEC was performed for 60 min with gemcitabine (1000 mg/m

resultsA total of 17 patients underwent CRS-HIPEC with gemcitabine for recurrent uLMS (median 55 years). Most patients had received prior systemic therapy (76%) and undergone at least two operations for uLMS (65%). Median PFS was 11 months, significantly longer than historical control of 3 months (p < 0.001). Median OS was not reached at follow up time over 3 years. The study was closed early due to slow accrual: at time of closure, two patients remained without evidence of disease recurrence. Median PCI was 7; all patients achieved CCR 0. There were no Clavien-Dindo grade 3 complications, and median postoperative stay was 7 days. Two patients experienced grade 4 toxicities (hypokalemia and neutropenia).

conclusionsCRS with gemcitabine HIPEC and adjuvant systemic chemotherapy is feasible without increased morbidity and has potential to improve outcomes and achieve long-term survival in patients with recurrent uLMS.

Indexed as

Cytoreduction Surgical ProceduresHyperthermic Intraperitoneal ChemotherapyLeiomyosarcomaNeoplasm Recurrence, LocalPeritoneal NeoplasmsUterine NeoplasmsAdultAgedCombined Modality TherapyDeoxycytidineFemaleFollow-Up StudiesGemcitabineHumansMiddle AgedPrognosisDeoxycytidineGemcitabine

Identifiers

PMID42104036

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.